What’s Propelling La Jolla Pharmaceutical Company (LJPC) to Increase So Much?

February 16, 2018 - By Larry Anderson

Investors sentiment decreased to 1.61 in 2017 Q3. Its down 0.20, from 1.81 in 2017Q2. It dived, as 10 investors sold La Jolla Pharmaceutical Company shares while 21 reduced holdings. 25 funds opened positions while 25 raised stakes. 23.31 million shares or 1.99% less from 23.78 million shares in 2017Q2 were reported.
Legal And General Grp Public Limited Com accumulated 4,429 shares or 0% of the stock. 47,557 are held by Eam Invsts Lc. Swiss Financial Bank stated it has 29,400 shares or 0% of all its holdings. Vanguard Group has invested 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Wells Fargo And Mn has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Price T Rowe Associates Md holds 307,879 shares. Grp Inc One Trading Lp invested in 4,240 shares. Alliancebernstein L P, New York-based fund reported 34,100 shares. Schwab Charles Investment Mngmt has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). California Public Employees Retirement, a California-based fund reported 42,300 shares. Raymond James Assoc holds 44,076 shares. Planning Corporation holds 15,650 shares. Financial Bank Of America De holds 49,395 shares or 0% of its portfolio. Deutsche Natl Bank Ag owns 55,291 shares for 0% of their portfolio. Ny State Common Retirement Fund reported 0% stake.

Since December 29, 2017, it had 0 insider buys, and 1 sale for $323,208 activity.

The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) is a huge mover today! The stock increased 4.10% or $1.35 during the last trading session, reaching $34.31. About 185,506 shares traded. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has risen 128.65% since February 16, 2017 and is uptrending. It has outperformed by 111.95% the S&P500.
The move comes after 5 months positive chart setup for the $759.80 million company. It was reported on Feb, 16 by Barchart.com. We have $36.71 PT which if reached, will make NASDAQ:LJPC worth $53.19 million more.

Analysts await La Jolla Pharmaceutical Company (NASDAQ:LJPC) to report earnings on February, 22. They expect $-1.26 earnings per share, up 12.50 % or $0.18 from last year’s $-1.44 per share. After $-1.19 actual earnings per share reported by La Jolla Pharmaceutical Company for the previous quarter, Wall Street now forecasts 5.88 % negative EPS growth.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ratings Coverage

Among 8 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 5 have Buy rating, 3 Sell and 0 Hold. Therefore 63% are positive. La Jolla Pharmaceutical Company had 18 analyst reports since August 11, 2015 according to SRatingsIntel. On Friday, December 8 the stock rating was downgraded by JP Morgan to “Underweight”. The firm has “Buy” rating given on Monday, June 12 by Jefferies. The rating was downgraded by Zacks on Tuesday, August 11 to “Hold”. The rating was initiated by Cowen & Co with “Outperform” on Tuesday, February 9. On Thursday, August 31 the stock rating was maintained by Jefferies with “Buy”. J.P. Morgan initiated La Jolla Pharmaceutical Company (NASDAQ:LJPC) on Wednesday, August 30 with “Buy” rating. The firm earned “Underperform” rating on Monday, February 12 by Jefferies. The rating was downgraded by J.P. Morgan on Friday, December 8 to “Sell”. The firm has “Buy” rating given on Tuesday, January 30 by H.C. Wainwright. The stock has “Buy” rating by Lake Street on Tuesday, May 24.

More recent La Jolla Pharmaceutical Company (NASDAQ:LJPC) news were published by: Benzinga.com which released: “Jefferies Downgrades La Jolla On Weak Forecast For Blood Pressure Drug” on February 12, 2018. Also Fool.com published the news titled: “Why Lumber Liquidators Holdings, Stamps.com, and La Jolla Pharmaceutical …” on February 12, 2018. Streetinsider.com‘s news article titled: “FDA Approves La Jolla Pharmaceutical’s (LJPC) Giapreza for Dangerously Low …” with publication date: December 21, 2017 was also an interesting one.

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company has market cap of $759.80 million. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. It currently has negative earnings. The firm is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: